304 related articles for article (PubMed ID: 30834050)
1. Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):35-45. PubMed ID: 30834050
[TBL] [Abstract][Full Text] [Related]
2. Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor.
Minami S; Ihara S; Komuta K
World J Oncol; 2019 Feb; 10(1):55-61. PubMed ID: 30834052
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
Front Oncol; 2021; 11():697865. PubMed ID: 34692478
[TBL] [Abstract][Full Text] [Related]
4. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
[TBL] [Abstract][Full Text] [Related]
5. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial.
Hopkins AM; Kichenadasse G; Abuhelwa AY; McKinnon RA; Rowland A; Sorich MJ
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803256
[TBL] [Abstract][Full Text] [Related]
6. A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer.
Zhang T; Xue W; Wang D; Xu K; Wu L; Wu Y; Zhou Z; Chen D; Feng Q; Liang J; Xiao Z; Hui Z; Lv J; Wang X; Deng L; Wang W; Liu W; Wang J; Zhai Y; Wang J; Bi N; Wang L
Radiother Oncol; 2021 Mar; 156():244-250. PubMed ID: 33418003
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer.
Wang W; Huang Z; Yu Z; Zhuang W; Zheng W; Cai Z; Shi L; Yu X; Lou G; Hong W; Zhang Y; Chen M; Song Z
Front Oncol; 2020; 10():572853. PubMed ID: 33163403
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy.
Zhou S; Ren F; Meng X
Front Immunol; 2022; 13():955944. PubMed ID: 36238280
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor.
Minami S; Ogata Y; Ihara S; Yamamoto S; Komuta K
World J Oncol; 2017 Dec; 8(6):180-187. PubMed ID: 29317963
[TBL] [Abstract][Full Text] [Related]
10. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Minami S; Ihara S; Nishimatsu K; Komuta K
World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
Kazandjian D; Gong Y; Keegan P; Pazdur R; Blumenthal GM
JAMA Oncol; 2019 Oct; 5(10):1481-1485. PubMed ID: 31343662
[TBL] [Abstract][Full Text] [Related]
12. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
[TBL] [Abstract][Full Text] [Related]
13. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a Systemic Inflammatory Biomarker in Advanced Bile Tract Carcinoma Treated with Anti-PD-1 Therapy: Prognostic and Predictive Significance of Lung Immune Prognostic Index Score.
Pan Y; Si H; Jia R; Deng G; Yan H; Fan M; Gou M; Chen S; Zhang N; Shi Y; Qian N; Dai G
J Oncol; 2022; 2022():1427779. PubMed ID: 35342416
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
16. Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index.
Ortega-Franco A; Hodgson C; Raja H; Carter M; Lindsay C; Hughes S; Cove-Smith L; Taylor P; Summers Y; Blackhall F; Califano R
Target Oncol; 2022 Jul; 17(4):453-465. PubMed ID: 35781861
[TBL] [Abstract][Full Text] [Related]
17. Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors.
Chen S; Huang Z; Jia W; Tao H; Zhang S; Ma J; Liu Z; Wang J; Wang L; Cui P; Zhang Z; Huang D; Wu Z; Zheng X; Hu Y
J Hepatocell Carcinoma; 2020; 7():289-299. PubMed ID: 33173757
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Arıkan R; Alkış H; Işık S; Yaşar A; Çelebi A; Majidova N; Sever N; Adlı M; Demircan NC
Cureus; 2023 Jun; 15(6):e40548. PubMed ID: 37465788
[TBL] [Abstract][Full Text] [Related]
19. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.
Sun T; Guo Y; Sun B; Chen L; Ren Y; Zhu L; Zhang L; Liu Y; Zheng C
Eur J Med Res; 2023 Jul; 28(1):225. PubMed ID: 37408056
[TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB.
Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X
Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]